New targeted therapy could bring relief to people with lichen planus
Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...
Lipella Pharma Shares Rise After Positive Trial Data for Oral Lichen Planus Treatment
Lipella Pharmaceuticals shares were up 37% to $4.18 after the company said it saw positive topline results from its Phase 2a dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse ...
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key MetricsFindings Highlight ...
FDA Approves Expanded Access Program For Lipella Pharma's LP-310 In Oral Lichen Planus; Stock Up
Lipella Pharmaceuticals Inc. (LIPO), a clinical-stage biotechnology company, Wednesday said that the U.S. Food and Drug ...